# BPC-157 TB-500 Dosage in the Research Literature: Species, Routes, Gaps

> BPC-157 TB-500 dosage as the research literature reports it — species-specific animal doses, routes studied, and the plain fact that no validated blend dose or human protocol exists.

Per-body-weight animal doses, the routes actually studied, and the honest gap where a validated blend dose would be.

## BPC-157 TB-500 Dosage in the Research Literature

There is no validated dose for the BPC-157 TB-500 blend. This page reports doses only as they appear in the literature — administered to a named species, by a named route, in a specific model — never as guidance for human use. Commercial "Wolverine" labeling commonly pairs the two peptides at fixed combined masses per vial (for example `~10 mg + ~10 mg`, or a combined `20 mg` vial), but no peer-reviewed combination dose-finding study exists [6].

The BPC-157 component, in rodent models, is most often expressed per body weight — frequently `~10 microg/kg` and `~10 ng/kg` in tissue-repair studies [1], with gastric-ulcer cytoprotection studied at `400-800 ng/kg` in rats. The TB-500 / Thymosin Beta-4 component spans a far wider range in animal work: `2-18 mg/kg` intraperitoneal in a rat embolic-stroke dose-response study (with an optimal modeled near `3.75 mg/kg`, and `18 mg/kg` giving no benefit — higher was not better), and `150 microg` twice weekly intraperitoneally for six months in the mdx muscular-dystrophy study [4].

Human single-agent reference points exist only for full-length Thymosin Beta-4, not the blend: intravenous Tβ4 was well tolerated to high single doses in early-phase work [4]. None of these numbers describes the combination, and none translates to a human protocol.

## Half-life, routes, and handling

### What is the half-life of BPC-157 and TB-500?

BPC-157's elimination half-life was reported as under 30 minutes (`t1/2 <30 min`) in a rat/dog pharmacokinetic study. No specific half-life is established for the TB-500 heptapeptide — human PK data are for full-length Thymosin Beta-4 — and none is validated for the blend [4].

### How is the Wolverine blend administered in research settings?

Subcutaneous and intramuscular are the predominant routes in the research community for the blend, though those routes come from community practice, not controlled human efficacy trials. The underlying rodent efficacy studies for both peptides used intraperitoneal administration [1][4]. Intravenous and local/topical routes appear in individual-compound studies.

### Can BPC-157 and TB-500 be taken orally?

BPC-157 is studied as a "stable gastric" peptide, which is why oral routes appear in its literature. Blend oral products are marketed but lack validated pharmacokinetics — there is no controlled study establishing oral bioavailability or a dose for the combination [6]. Oral handling is research context, not human-use guidance.

### How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. This is research-handling context only, not human-use instruction.

## The per-day and cycling questions

### Is there a per-day dose for the BPC-157 / TB-500 blend?

No controlled per-day combination dose exists. Community "loading then maintenance" protocols and fixed-ratio vials have no controlled-trial basis and should not be read as validated dosing [6]. The mixed preclinical dose-response data — including a TB-500/Tβ4 study where the highest dose gave no benefit — actively undercut "more is better" loading schemes [4].

### How often should you inject BPC-157 and TB-500?

There is no validated injection schedule for the blend. Community frequency protocols are not derived from controlled trials. Reported animal dosing frequencies (such as the twice-weekly six-month Tβ4 schedule in the mdx study) are species- and model-specific and do not define a human schedule [4].

### How do you cycle BPC-157 and TB-500?

No controlled human trial defines a cycle for the blend. Community cycling and "loading then maintenance" schemes are not validated. The reported animal doses are expressed per body weight in species-specific models [1][4] and do not translate to human cycling protocols. Everything on this page is dosing *context* from the literature, not a recommendation.

---

A street-wall research digest on the BPC-157 TB-500 Wolverine blend — each peptide tagged to its own studies, every blend-level gap sprayed in plain sight beside the FDA 503A line, with no clinic behind the wall and nothing here to dispense.